Hi, today we are going to talk about Catalyst Biosciences and its current landscape.
Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the company entered into a global science collaboration agreement with Biogen for the development and commercialization of pegylated CB-2782. Catalyst Biosciences it's going to receive $15 million upfront payment and is poised to receive up to $340 million down the road, also royalties of the sales. A context that sets Catalyst Biosciences to a skyrocket movement as is expected that its earnings are going to overcome expectations in the next quarters easily than ever.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the company entered into a global science collaboration agreement with Biogen for the development and commercialization of pegylated CB-2782. Catalyst Biosciences it's going to receive $15 million upfront payment and is poised to receive up to $340 million down the road, also royalties of the sales. A context that sets Catalyst Biosciences to a skyrocket movement as is expected that its earnings are going to overcome expectations in the next quarters easily than ever.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.